Progenics (PGNX) volatility elevated into FDA approval of constipation treatment

Progenics Pharma (NASDAQ: PGNX) August call option implied volatility is at 177, September is at 133; compared to its 52-week range of 57 to 173 into Valeant Pharmaceuticals International (VALEANT) and Progenics Pharmaceuticals announced that the FDA has approved RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

You May Also Be Interested In

• Micron Technology (MU) call put ratio 1.2 calls to 1 put into quarter results
• Johnson Controls (JCI) 4K contracts of August 120 puts trade, share price down 4%
• Americas Silver Corporation (USAS) 14K contracts of August 6 calls trade, share price down 8%